Exciting Advancements in ADC Therapies Unveiled at ASCO 2025
Key Highlights from the ASCO 2025 Meeting
The recent ASCO Annual Meeting showcased groundbreaking advancements in cancer treatment, particularly through the oral presentations by Duality Bio, a clinical-stage biotech company dedicated to developing next-generation antibody-drug conjugates (ADCs). During the event, notable findings on the B7H3 ADC candidate DB-1311/BNT324 and the HER3 ADC candidate DB-1310 were presented, illustrating promising results in the pursuit of innovative therapies for cancer.
B7H3 ADC Candidate DB-1311/BNT324
One of the pivotal presentations focused on the B7H3-targeted ADC candidate, DB-1311/BNT324, which is being jointly developed with BioNTech. The ongoing Phase 1/2 clinical trial has delved into its effectiveness in patients suffering from heavily pre-treated castration-resistant prostate cancer (CRPC). The presented data indicated promising early clinical activity alongside a manageable safety profile, with low discontinuation rates among participants.
In this trial, which featured a total of 52 efficacy evaluable patients, a confirmed objective response rate of 30.8% was achieved, with a disease control rate (DCR) of 90.4%. Notably, for 68 evaluable patients, the six-month radiographic progression-free survival (rPFS) rate stood at 69.8%. Results were consistent across both dosing levels of 6 mg/kg and 9 mg/kg, suggesting the therapy's effectiveness in various treatment scenarios, including earlier treatment lines and among patients with distinct metastatic profiles.
The clinical trial is currently expanding to enroll patients with different cohorts, such as those recently treated with Lu-177 CRPC and taxane-naïve CRPC, addressing the growing need for effective treatments in prostate cancer.
HER3 ADC DB-1310
Turning to another promising candidate, the HER3 ADC, DB-1310, attracted attention during the meeting. Presented by Professor Aaron E. Lisberg from UCLA, the Phase I/IIa study revealed that DB-1310 demonstrates significant potential against advanced solid tumors, particularly for patients who have exhausted standard treatment options.
Among 123 efficacy evaluable patients, the unconfirmed objective response rate reached 31%, while the disease control rate achieved an impressive 84%. The most noteworthy results emerged from patients with EGFR-mutated non-small cell lung cancer (NSCLC) where the uORR surged to 44%, and DCR reached 91%. Median progression-free survival for this subgroup was recorded at 7.0 months, alongside a median overall survival of 18.9 months, proving the efficacy of DB-1310 in challenging cases.
Moreover, DB-1310 showed a favorable safety profile. The treatment-related adverse events primarily included grade 1-2 hematological and gastrointestinal issues, with a low treatment-related discontinuation rate of just 3.5%. These results bolster the continued development of DB-1310, particularly with an eye on its application in EGFR-mutated NSCLC patients.
About Duality Bio
Duality Biotherapeutics, recognized for its innovative approaches in cancer treatment, is revolutionizing the landscape with its dedicated focus on ADCs. The company is expanding its clinical trials across numerous countries, having enrolled over 2,000 patients in search of effective therapies to combat diverse cancers.
With a robust portfolio and cutting-edge ADC technology platforms, Duality Bio is committed to exploring various applications for its candidates, including combinations with targeted therapies. As they progress, the company is forging strategic partnerships with leading biotech innovators, further cementing its position in the global landscape of cancer therapeutics.
Frequently Asked Questions
What is DB-1311/BNT324 used for?
DB-1311/BNT324 is an antibody-drug conjugate candidate targeting B7H3, designed to treat heavily pre-treated castration-resistant prostate cancer.
What were the results from the recent clinical trial for DB-1311?
The trial showed a confirmed objective response rate of 30.8% and a disease control rate of 90.4% among patients, demonstrating early clinical activity.
Who presented the findings on DB-1310?
The findings for DB-1310 were presented by Professor Aaron E. Lisberg from UCLA, showcasing its effectiveness against advanced solid tumors.
What is the significance of these ADC candidates?
Both candidates represent new advancements in cancer therapy, aimed at addressing critical unmet needs in treatment, particularly for resistant forms of cancer.
How is Duality Bio advancing its ADC candidates?
Duality Bio is expanding clinical trials globally and exploring new combinations with other therapies to enhance the efficacy of their ADC candidates.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
